CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

Abu Dhabi achieved a medical milestone on January 5, 2026, with the UAE's first gene-therapy injection for inherited blood disorders. CASGEVY, utilizing CRISPR-Cas9, corrects faulty DNA in conditions ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

Restricted access to genome-editing technologies poses serious challenges for countries like India that urgently need such ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

Advanced engineered cell therapies require gene editing tools that are both precise and efficient. In recent years, CRISPR-Cas9 has emerged as the gold standard for editing genes with greater ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...